Gerald Crabtree, MD, a developmental biologist at Stanford, and a lead author of the study examined the potential rewiring of cancer cells to activate “cell death genes.”
The study focused on large B cell lymphoma. By linking together BRD4 and BCL6 proteins, researchers produced a molecule known as TCIP1 — capable of destroying diffuse large B cell lymphoma cell lines as well as those that are chemotherapy-resistant.
It could eventually be used on half of all cancers, Dr. Crabtree told The New York Times.
While the research didn’t lead to a drug development for cancer patients, the findings could be used as impetus for that in the future, according to the Times.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
